Pharmaceuticals, Biotechnology and Life Sciences
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
BURLINGTON, Mass.–(BUSINESS WIRE)–$SCPH #FUROSCIX–scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential…
Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx, said that the company will release topline data from the LUMINA-2 study of CCX140.
Moderna said that after two doses all participants evaluated to date across the 25 µg and 100 µg dose cohorts…
Leinco Technologies and Vanderbilt University Medical Center (VUMC) have agreed to scale up production of its most promising antibodies for development of a rapid, point of care COVID-19 diagnostic test.
– Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall – – Approval…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create…
IMV is preparing to advance a DPX-based vaccine candidate for COVID-19, which is on track to enter into clinical trials later this summer.
Stoke Therapeutics is on track to begin enrollment and dosing of STK-001 in Part A of Phase 1/2a “Monarch” clinical trial in children and adolescents with Dravet syndrome in 2H 2020.
The company reported a net loss of $8.2 million, or $0.47 per share, for the three months ended March 31, 2020, compared to a net loss of $4.9 million, or $0.52 per share, for the same period in 2019. The company had $11.8 million in cash and cash equivalents as of March 31, 2020.